Daily Endocrinology Research Analysis
Analyzed 124 papers and selected 3 impactful papers.
Summary
Three high-quality randomized trials advance metabolic therapeutics. A phase 3 NEJM study shows the dual glucagon/GLP-1 agonist survodutide produces clinically meaningful weight loss versus placebo. Two Lancet REIMAGINE trials demonstrate that fixed-dose cagrilintide–semaglutide (CagriSema) improves glycemic control and weight versus semaglutide alone and is effective as an add-on to basal insulin.
Research Themes
- Dual-agonist and multi-hormonal pharmacotherapy for obesity and type 2 diabetes
- Head-to-head active comparator RCTs informing treatment escalation
- Integration of weight loss and glycemic control across therapeutic contexts
Selected Articles
1. Survodutide Once Weekly for the Treatment of Adults with Obesity.
In a phase 3, double-blind RCT of 725 adults with obesity but without diabetes, once-weekly survodutide (3.6 or 6.0 mg) produced −12.2% and −13.0% mean weight loss at 76 weeks versus −5.4% with placebo. Gastrointestinal events were the most common adverse events and were usually mild-to-moderate.
Impact: Demonstrates robust efficacy of a first-in-class glucagon/GLP-1 dual agonist in a large phase 3 trial, informing next-generation anti-obesity therapeutics.
Clinical Implications: Survodutide may offer a potent, once-weekly pharmacologic option for obesity management with clinically meaningful weight loss; clinicians should monitor for gastrointestinal tolerability.
Key Findings
- At week 76, mean body-weight change was −12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo.
- ≥5% weight loss was achieved in 72.6% and 71.9% with survodutide vs 46.3% with placebo (P<0.001).
- Gastrointestinal adverse events were common (81–90% on survodutide vs 48% placebo), typically mild-to-moderate; no deaths occurred.
Methodological Strengths
- Large, multicenter, double-blind, randomized phase 3 design with treatment-regimen estimand
- Pre-specified dual primary endpoints and robust comparison to placebo plus lifestyle counseling
Limitations
- Adverse events were predominantly gastrointestinal; long-term safety beyond 76 weeks remains to be characterized
- Exclusion of individuals with diabetes may limit generalizability to broader metabolic populations
Future Directions: Assess long-term safety and cardiometabolic outcomes, head-to-head comparisons with other advanced incretin-based or multi-agonist therapies, and real-world effectiveness.
BACKGROUND: Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain. Survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist, led to substantial weight reduction in a phase 2 trial involving adults with obesity without diabetes. METHODS: In this phase 3, double-blind trial, we randomly assigned adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher, or 27 or higher with at least one obesity-related complication (excluding diabetes), in a 1:1:1 ratio to receive once-weekly survodutide administered subcutaneously at a dose adjusted up to 3.6 mg or 6.0 mg or placebo, in addition to counseling for lifestyle modification. The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76. The primary efficacy analysis was conducted according to the treatment-regimen estimand, which incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and a prolonged dose-escalation period. RESULTS: Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men. At baseline, the mean BMI was 37.9, and the mean body weight was 108.8 kg. At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo). The most common adverse events were gastrointestinal symptoms (typically mild to moderate), which occurred in 80.9% of the participants in the 3.6-mg group, in 89.7% of those in the 6.0-mg group, and in 47.9% of those in the placebo group. No deaths were reported. CONCLUSIONS: Survodutide led to significantly greater reductions in body weight than placebo in adults with obesity without diabetes. (Funded by Boehringer Ingelheim; SYNCHRONIZE-1 ClinicalTrials.gov number, NCT06066515.).
2. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
In adults with type 2 diabetes on basal insulin, adding once-weekly fixed-dose cagrilintide–semaglutide (2.4 mg or 1.0 mg each) met the primary endpoint with statistically significant and clinically meaningful HbA1c reduction versus placebo. Weight also improved, addressing two key shortcomings of basal insulin regimens.
Impact: Provides phase 3 evidence that an amylin–GLP-1 fixed-dose combination improves glycemia and weight when added to basal insulin, informing treatment intensification pathways beyond insulin up-titration.
Clinical Implications: For patients inadequately controlled on basal insulin, adding CagriSema may reduce HbA1c and weight, potentially lowering insulin requirements and mitigating weight gain; clinicians should monitor for typical incretin-related gastrointestinal effects.
Key Findings
- Randomized, double-blind, multicenter phase 3 study (n=274) compared CagriSema (2.4 mg or 1.0 mg each) versus placebo added to basal insulin.
- Both CagriSema doses met the primary endpoint with statistically significant and clinically relevant HbA1c reductions versus placebo.
- Body weight decreased with CagriSema, addressing weight gain commonly seen with basal insulin regimens.
Methodological Strengths
- Double-blind, randomized, placebo-controlled, multicenter phase 3 design
- Evaluation as add-on to standard-of-care basal insulin enhances external validity for real-world practice
Limitations
- Abstract does not provide detailed hypoglycemia rates or full safety profile
- Moderate sample size limits subgroup analyses
Future Directions: Define hypoglycemia risk, insulin dose adjustments, and long-term cardiovascular and renal outcomes; compare against GLP-1/GIP or other incretin combinations.
BACKGROUND: Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. METHODS: This double-blind, parallel-group, randomised, controlled, phase 3a study (REIMAGINE 3) was done at 46 centres (university hospitals, health-care centres, research centres, and other clinical trial sites) in six countries (the USA, China, Japan, Serbia, Slovakia, and South Africa). Adults with type 2 diabetes (glycated haemoglobin [HbA FINDINGS: Between March 26 and Nov 29, 2024, we screened 340 individuals and 274 were included and randomly assigned to cagrilintide-semaglutide (2·4 mg each; n=90), cagrilintide-semaglutide (1·0 mg each; n=93), or placebo (pooled; n=91). Mean baseline HbA INTERPRETATION: Cagrilintide-semaglutide at doses of 2·4 mg each and 1·0 mg each met the primary endpoint, with statistically significant and clinically relevant HbA
3. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
In a global, double-blind phase 3 trial (n=2713), fixed-dose cagrilintide–semaglutide 2.4 mg each was superior to semaglutide 2.4 mg for HbA1c reduction, with additional weight benefits. The combination also outperformed lower-dose comparators and maintained treatment through 68 weeks in most participants.
Impact: First large head-to-head phase 3 evidence that an amylin–GLP-1 fixed-dose combination exceeds GLP-1 monotherapy for glycemic control (and weight), shaping future treatment algorithms.
Clinical Implications: For patients needing escalation beyond GLP-1 RA monotherapy, CagriSema offers greater HbA1c and weight reduction; selection should weigh efficacy gains against tolerability and access.
Key Findings
- Large, global, double-blind, randomized trial enrolled 2713 adults with inadequately controlled type 2 diabetes.
- CagriSema 2.4 mg each was superior to semaglutide 2.4 mg for HbA1c reduction; weight outcomes favored CagriSema.
- High treatment persistence through week 68 (87.6% on treatment), supporting long-term use feasibility.
Methodological Strengths
- Head-to-head, active-controlled design with multiple relevant comparators and placebo
- Large sample size across 30 countries with double-blind conduct and long (68-week) treatment exposure
Limitations
- Abstract lacks detailed safety breakdown by comparator arm
- Generalizability to non-trial settings and diverse ancestries still requires real-world validation
Future Directions: Evaluate cardiovascular outcomes, durability after discontinuation, and cost-effectiveness; define positioning versus GLP-1/GIP dual agonists.
BACKGROUND: The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overweight or obesity. METHODS: REIMAGINE 2 was a randomised, double-blind, placebo-controlled and active-controlled, parallel-group study conducted in 30 countries (trial sites included university hospitals, health-care centres, research centres, and other centres). Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA FINDINGS: From Oct 10, 2023, to July 29, 2024, 3593 people were screened for eligibility, 2713 of whom were randomly assigned to cagrilintide-semaglutide (2·4 mg each; n=603), semaglutide 2·4 mg (n=605), cagrilintide 2·4 mg (n=152), cagrilintide-semaglutide (1·0 mg each; n=595), semaglutide 1·0 mg (n=609), or placebo (pooled 2·4 mg and 1·0 mg; n=149). 1164 (42·9%) of 2713 were female, 1549 (57·1%) were male, and 2207 (81·3%) were White. Of the randomly assigned participants, 2595 (95·7%) completed the study and 2376 (87·6%) were on treatment at week 68. Mean baseline HbA INTERPRETATION: Cagrilintide-semaglutide (2·4 mg each) was superior to semaglutide 2·4 mg in reducing HbA